Stage IV Cutaneous Melanoma AJCC v6 and v7 Recruiting Phase 1 / 2 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0091050 (Stage IV Cutaneous Melanoma AJCC v6 and v7)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03384836Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by SurgeryTreatment
NCT03325101Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by SurgeryTreatment